Delta Health has discontinued giving the monoclonal antibody (MAB)s Regeneron and Bamlanivimab/Etesevimab in response to the FDA limiting the use of these certain Monoclonal Antibodies to Treat COVID-19. Revising the emergency use authorizations of these two monoclonal antibody treatments due to their limited response to the novel coronavirus, SARS-CoV-2 (COVID-19) Omicron variant. Delta Health continues to offer Sortrovimab the only MAB known to be effective against Omicron.
Monoclonal antibodies (MAB) are laboratory-produced molecules that act as substitute antibodies that can restore, enhance or mimic the immune system’s attack on cells.
The state of Colorado has limited supplies of the MAB, therefore Delta Health has a very limited supply to offer to the community. The organization’s allotment the next week is six doses with little hope for further supply. This situation is likely to change as our supply of Sotrovimab becomes more reliable.
“ We are limiting our use to only those patients with the highest risk,” states Jody Roeber, Chief Clinical Officer and part of the Unified Command for Delta County. “At this time, Delta Health is only taking referrals for Delta County residents as we are the sole provider for this community, and our obligation is with our community residents.”
High Risk is defined as Tier 1 and 2 patients: Immunosuppressed, pregnant, OR unvaccinated >75 OR unvaccinated <75 AND with significant risk factors for more severe disease. Vaccinated status includes those who completed the primary vaccine series, with or without a booster.
From early on in the pandemic, Delta Health anticipated the need for further therapeutics and registered into the state’s REDcap registry program. Delta Health has continued to receive this medication when other local facilities have not because of the early initiative. The hospital has been diligent in following all expectations required to give monoclonal antibodies.
Delta Health has found MAB to be highly successful in decreasing hospitalizations rates and the progression to severe disease and death for patients with mild to moderate COVID-19.
